cancer drug

Gilead to Buy Cancer Drugmaker for $21 Billion
M&A

Gilead to Buy Cancer Drugmaker for $21 Billion

The acquisition of Immunomedics "represents significant progress in Gilead’s work to build a strong and diverse oncology portfolio."
By Matthew Heller | September 14, 2020
Read More
Gilead Flies Into Cancer Therapy With Kite Deal
Strategy

Gilead Flies Into Cancer Therapy With Kite Deal

The $11.9 billion acquisition gives Gilead access to the oncology market as its hepatitis C drugs face declining sales.
By Matthew Heller | August 28, 2017
Read More
Takeda Buys Ariad in $5.2B Cancer Drug Bet
Strategy

Takeda Buys Ariad in $5.2B Cancer Drug Bet

The Japanese drug giant is paying a 75% premium for Ariad to "transform our global solid tumor franchise."
By Matthew Heller | January 10, 2017
Read More
Pfizer Makes Cancer Play With Medivation Deal
Strategy

Pfizer Makes Cancer Play With Medivation Deal

The $14 billion acquisition would add the best-selling prostate cancer drug Xtandi to Pfizer's growing oncology portfolio.
By Matthew Heller | August 22, 2016
Read More